Status and phase
Conditions
Treatments
About
The study will evaluate the efficacy of alpha-lipoic acid(α-LA) on mortality in patients with ischemic heart failure (NYHA Class II - IV and EF =< 45%).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
patients ≥ 18 years of age, male or female.
Patients with a diagnosis of AMI (>30 days) according to the global definition. ③Patients with a diagnosis of CHF (NYHA class II-IV) and reduced ejection fraction (EF =< 45%) and elevated BNP(NT-proBNP≥600pg/ml or BNP≥150pg/ml; NT-proBNP ≥400 pg/mL or BNP ≥100 pg/mL if patients was hospitalized for heart failure within 12months).
Patients must be treated with standardized heart failure medications treatment at a stable dose for at least 4 weeks.
Exclusion criteria
Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
allergy to any of the study drugs, drugs of similar chemical classes(Vitamin B) as well as known or suspected contraindications to the study drugs.
Previous history of intolerance to recommended target doses of α-LA.
Current acute decompensated HF (exacerbation of chronic HF manifested by signs and symptoms that may require intravenous therapy).
⑤ Symptomatic hypotension and/or a SBP < 100 mmHg.
⑥ Severe liver function abnormalities (ALT or AST more than 3 times of the normal upper limit).
⑦ Estimated GFR < 30 mL/min/1.73m2 as measured by the simplified MDRD formula.
⑧ Serum potassium > 5.2 mmol/L.
⑨ Pregnant women or women preparing for birth.
Primary purpose
Allocation
Interventional model
Masking
300 participants in 2 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal